The second issue of the open-access journal showcases multidisciplinary heart failure research and the many intersections that shape patient care.
Adverse changes in the heart’s structure and function are common in people with chronic kidney disease (CKD), warranting mitigating therapies.
Pharmaceuticals announced that new sotagliflozin clinical data was presented at the American Heart Association, AHA, Annual ...
According to the American College of Cardiology, nearly 6.7 million Americans have heart failure, more than half with preserved ejection fraction. This condition often leads to frequent ...
The Phase 2, randomized, double-blind clinical trial included 23 patients randomized to either 200 mg ataciguat (n=12) or placebo (n=11) once daily for a 12-month period. The primary Phase 2 clinical ...
Objective The left atrial stiffness index (LASI) has been proven to be a promising marker for assessing left atrial (LA) and ...
RICHMOND, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and third quarter 2025 financial ...
Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC.
Background: Left ventricular (LV) diastolic function relies on active myocardial relaxation and passive cardiac chamber stiffness and is assessed by echocardiography. Abnormal LV diastolic function ...
Introduction: Patients with HFpEF present a higher prevalence of major depressive disorder MDD (13%) than patients with HFrEF (6%). Several studies report that HFpEF and depression, share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback